Medicaid Reimbursement for Vagus Nerve Stimulation

Beginning July 1, 2025, the bill requires the department of health care policy and financing to reimburse acute care hospitals and ambulatory surgery facilities that provide vagus nerve stimulation therapy to members diagnosed with drug-resistant epilepsy at a rate that is equal to 75% of the cost for acquiring the vagus nerve stimulator device, which reimbursement is in addition to and does not supplant the reimbursement for any necessary surgical procedure associated with implanting the device.
(Note: This summary applies to this bill as introduced.)